Free tool
FAERS Monitor: Posfrea
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 203050 or its brand name (Posfrea, Palonosetron Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
3,601
Serious
3,304
92% of reports
Hospitalization
1,783
Death reported
566
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- nausea443
- diarrhoea264
- fatigue264
- vomiting263
- febrile neutropenia259
- neutropenia254
- alopecia229
- anaemia203
- dyspnoea201
- off label use201
- decreased appetite191
- death190
- pyrexia176
- asthenia158
- constipation156
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 7 |
| 2005 | 21 |
| 2006 | 13 |
| 2007 | 18 |
| 2008 | 28 |
| 2009 | 24 |
| 2010 | 27 |
| 2011 | 38 |
| 2012 | 101 |
| 2013 | 69 |
| 2014 | 120 |
| 2015 | 159 |
| 2016 | 170 |
| 2017 | 189 |
| 2018 | 322 |
| 2019 | 244 |
| 2020 | 207 |
| 2021 | 317 |
| 2022 | 325 |
| 2023 | 282 |
| 2024 | 287 |
| 2025 | 393 |
| 2026 | 240 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,558 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| febrile neutropeniaSignal | 259 | 22.9 | 20.4 | 5,396 |
| neutropeniaSignal | 254 | 10.9 | 9.7 | 2,292 |
| alopeciaSignal | 229 | 6.8 | 6.0 | 1,140 |
| anaemiaSignal | 203 | 6.2 | 5.4 | 892 |
| decreased appetiteSignal | 191 | 4.8 | 4.2 | 578 |
| constipationSignal | 156 | 4.2 | 3.6 | 378 |
| nauseaSignal | 443 | 3.3 | 3.0 | 723 |
| vomitingSignal | 263 | 3.3 | 2.9 | 421 |
| pyrexiaSignal | 176 | 3.0 | 2.6 | 232 |
| astheniaSignal | 158 | 2.5 | 2.1 | 137 |
| diarrhoeaSignal | 264 | 2.4 | 2.1 | 219 |
| dyspnoeaSignal | 201 | 2.1 | 1.8 | 114 |
| fatigue | 264 | 2.0 | 1.8 | 132 |
| off label use | 201 | 1.3 | 1.2 | 18 |
| death | 190 | 1.3 | 1.1 | 12 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.